US Patent 10,035,766 (Method Claims for Type 1 Gaucher’s Disease): Claim Scope, Competitive Patent Landscape, and US Generic/Biosimilar Entry Risk
US Patent 10,035,766 is directed to a method for treating type 1 Gaucher’s disease using a specific “Formula III” compound family (and optional combination with imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol). The claim set is narrow at the clinical level (type 1 Gaucher’s disease) but broad at the compound-structure level within the defined substitution pattern (R1, R2, R3, R4, R7, R8). The enforceable US value hinges on: (1) whether competitors use the same or design-around Formula III variants; (2) whether combination therapy is required or optional under dependent claims; and (3) whether there are earlier blocking patents on the same scaffolds or process patents that affect manufacturing or infringement positions even when the active ingredient differs.
Method Claims for Type 1 Gaucher’s Disease Using “Formula III” Compounds: What exactly does US 10,035,766 cover?
Core independent claim (Claim 1)
A method for treating type 1 Gaucher’s disease in a patient by administering an effective amount of a “compound of Formula III” defined by substitution rules:
- R¹ is C(R²)(R³)(R⁴)
- R² is hydrogen or fluorine
- R³ is fluorine
- R⁴ is fluorine, C1-4 alkyl, or phenyl
- R⁷ is –OH
- R⁸ is hydrogen
This is a classic “therapeutic use” claim paired with a tightly constrained chemical genus. The patent’s infringement posture in the US is mainly a drug-on-drug (or molecule-on-molecule) substitution story: if an infringing product contains an active meeting the Formula III definition, the prescribing/using clinician activity (or label-directed administration, depending on the claim construction) can support method infringement.
How the substitution constraints narrow the chemical genus
Claim 1’s key structural knobs:
- R³ fixed to fluorine
- R² limited to H or F (a two-option set)
- R⁴ limited to F, C1-4 alkyl, or phenyl
- R⁷ fixed to –OH and R⁸ fixed to H
That creates a finite enumerated sub-genus rather than a wide “any substituted aryl” freedom-to-operate situation. Practically, this matters because many “nearby” analogs are only one atom or one substituent away, and claim charts often turn on whether the competitor’s analog still contains:
- the same fixed fluorination pattern (R³ = F), and
- the R⁷ hydroxyl and R⁸ hydrogen positions.
Dependent claim coverage: combination therapy and fixed substituents
- Claim 2 adds “further comprising” administering another therapeutic agent. This can create a second infringement pathway when the method is practiced in combination regimens.
- Claim 3 specifies the other therapeutic agent as imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (commonly referred to as miglustat in the Gaucher context).
- Claims 4–8 lock particular substitution choices:
- Claim 4: R² = hydrogen
- Claim 5: R² = fluorine
- Claim 6: R⁴ = fluorine
- Claim 7: R⁴ = C1-4 alkyl
- Claim 8: R⁴ = phenyl
These dependent claims are valuable in two ways:
- They can reduce prior-art ambiguity in validity challenges by focusing the chemical scope.
- They increase the chance that an accused product maps into at least one subgroup even if the exact genus claim is disputed.
Clinical scope: type 1 Gaucher’s disease
The claim is limited to type 1 Gaucher’s disease. If a competitor labels or uses the compound for type 2 or type 3 Gaucher’s, it may avoid literal infringement while still competing on an efficacy/market basis. In enforcement, the label indications and real-world usage patterns usually matter.
What patents protect Formula III compounds for Gaucher treatment in the US? How do you expect the landscape to look?
A comprehensive landscape for US Patent 10,035,766 requires identifying:
- the patent family of 10,035,766 (priority, earlier filings, continuation chain),
- earlier compound/chemical patents that define the scaffold and specific substitution patterns,
- any process/manufacturing patents for the same actives,
- and later formulation/regimen patents that keep the same active in play with dosing and combination regimens.
However, based only on the claim text provided, the landscape cannot be fully enumerated (no patent number, assignee, priority dates, or active ingredient name is supplied). The analysis below therefore focuses on the claim-driven patent categories and infringement vectors that typically surround this exact claim structure.
Landscape categories that most likely intersect US 10,035,766
-
Genus chemical claims (core scaffold)
- Earlier patents often claim the same “Formula III” (or a broader genus that includes Formula III) as compounds per se.
- If those earlier patents exist, 10,035,766 can still matter for enforceability through method claims even when compound per se claims are weaker or expired, depending on priority and maintenance status.
-
Therapeutic method claims for Gaucher
- Independent method claims may appear for:
- type 1 Gaucher treatment,
- dosing regimens,
- patient populations and endpoints,
- combination therapy.
- If another patent already covers the therapeutic use, 10,035,766 may be redundant from an enforcement perspective but still strengthens bargaining leverage in settlements by expanding claim coverage.
-
Combination therapy claims (imiglucerase and miglustat)
- Claim 3 explicitly names imiglucerase and the small-molecule substrate reduction therapy miglustat.
- The landscape likely includes:
- claims for combination regimens of substrate reduction + enzyme replacement,
- claims for switching or step-down/step-up dosing approaches.
- This creates a competition between:
- enforcement based on “further comprising” logic (Claim 2),
- and design-around by avoiding the named other agent or avoiding type 1 labeling.
-
Design-around chemical analog patents
- Competitors often file analog series with minor changes to R²/R³/R⁴ definitions.
- Because Claim 1 fixes R³ = F and constrains R⁷ and R⁸, design-arounds likely target these positions first.
-
Manufacturing/process and intermediate patents
- Even if a competitor avoids literal infringement on the active’s formula, it can still face exposure on intermediates if the competitor uses the same synthetic route.
- Conversely, if a competitor changes the route, process patents may weaken infringement assertions for method claims if direct product composition claims are absent.
When does US 10,035,766 lose exclusivity? What generic entry risks exist for Formula III alternatives?
Exclusivity timing is determined by:
- patent term from earliest US non-provisional filing (plus PTA),
- any terminal disclaimers,
- maintenance status,
- and whether any regulatory exclusivity (not typical for new chemical entity methods) extends effective market protection.
With only the claim text and no filing dates or bibliographic data, no precise expiration can be stated. Still, you can model the generic entry risk as follows:
Generic risk framework for method patents
For method claims like Claim 1:
- A generic company must infringe by practicing the method, not merely by selling a compound, depending on jurisdiction and enforcement strategy.
- If the competitor markets a compound that falls within the Formula III definition, the risk increases through:
- label indications,
- promotional materials,
- clinician prescribing practices.
Combination claim risk: “further comprising” named therapies
Claim 3 narrows the combination partner to imiglucerase or miglustat. That creates two distinct design-around strategies for generic/competitor entrants:
- Use a Formula III compound that does not infringe genus because of substitution differences (R²/R⁴).
- If it does infringe genus, avoid the combination partner in claimed combinations, or run a different clinical pathway outside the dependent claim’s explicit combination recitation.
Subgroup carveouts: R² and R⁴ fixed-in dependent claims
In validity or infringement disputes, these dependent claims often become fallback positions. If a competitor’s product matches one substitution set (for example R² = F but R⁴ differs), it may still trigger Claim 5 or Claim 6 depending on mapping. If the competitor changes both R² and R⁴ to non-covered options, it is more likely to avoid all dependent claim literal reach.
How strong is the patent estate for this Gaucher method: is the claim likely to be valid vs designed-around?
Strength and vulnerability depend on:
- whether Formula III is genuinely novel over the prior art at filing,
- whether the method is not obvious in view of known Gaucher therapies,
- and whether the chemical definition is sufficiently definite to exclude close analogs.
In the absence of the patent’s specification, priority dates, and the identity of the actual Formula III compound(s), the most reliable risk assessment is structural:
Key validity pressure points for this claim format
-
Known fluorinated scaffold analogs
- If close fluorinated analogs existed in the prior art with -OH and fluorination at similar positions, the genus could face obviousness arguments.
- The claim’s fixed R³ = F and R⁷ = –OH help but do not eliminate obviousness if the prior art already suggested that pattern.
-
Known Gaucher method-of-treatment
- If multiple therapies already existed for type 1 Gaucher, method claims can still be patentable if the claimed compound’s therapeutic effect is non-obvious.
- But “administering an effective amount” plus a constrained compound genus can be attacked as predictable.
-
Combination therapy obviousness
- Claim 3’s explicit combination with imiglucerase or miglustat can be vulnerable if combination regimens were already known or clinically suggested.
Key enforceability pressure points
-
Literal mapping
- Claim 1 depends on whether an accused drug meets all R-group definitions.
- Even a single substituent mismatch (e.g., R⁴ = substituent not in F/alkyl/phenyl) can defeat literal infringement.
-
Patient selection and indication
- Type 1-only limitation reduces risk for off-label use outside type 1.
-
Proof burden
- Enforcing method claims often requires proof of actual administration consistent with claim limitations, not just potential capability.
Which companies are likely competing against US 10,035,766, and how do they typically try to invalidate or avoid it?
The only named comparators in the claims are imiglucerase and miglustat. That suggests the patent sits in the broader Gaucher treatment ecosystem where:
- enzyme replacement products compete on infusion and uptake,
- substrate reduction therapy competes on oral administration and chronic management.
Competitors typically pursue one or more of these lanes:
- Invalidity challenges aimed at novelty/obviousness of the chemical genus or the method limitation.
- Design-around altering R-group substitution patterns (especially R³, R⁷, R⁸, and R⁴).
- Non-infringing regimen strategies avoiding the combination therapy partner named in dependent claim 3.
A full list of specific defendant companies and litigants cannot be produced from the claim text alone.
Detailed claim chart logic: how to test infringement quickly against an accused Formula III analog
For any candidate compound, infringement mapping for Claim 1 is mechanical:
- Confirm the molecule’s core scaffold matches Formula III.
- Verify:
- Verify the branching substituent:
- R¹ = C(R²)(R³)(R⁴) with the correct bond/attachment.
- Verify substitution options:
- R² ∈ {H, F}
- R⁴ ∈ {F, C1-4 alkyl, phenyl}
If all are satisfied and the method is practiced to treat type 1 Gaucher’s disease, Claim 1 is in play.
For Claim 2 and Claim 3:
- Add a “further comprising” requirement for an additional therapeutic agent.
- For Claim 3, the additional agent must be imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol.
For Claims 4–8:
- The substitution must match the specific fixed R² and/or R⁴ selections.
Key takeaways
- US Patent 10,035,766 is a type 1 Gaucher’s disease method-of-treatment patent with chemical limitation to a Formula III fluorinated/-OH genus defined by fixed R-group rules (not an open-ended substitution claim).
- The enforcement value is driven by literal chemical mapping (R³ = F; R⁷ = –OH; R⁸ = H; R² ∈ {H,F}; R⁴ ∈ {F, C1-4 alkyl, phenyl}) and by whether the accused regimen uses imiglucerase or miglustat (dependent Claim 3).
- The strongest design-around routes are substitution changes that move compounds outside the R²/R⁴ enumerated sets or avoidance of the dependent combination context.
- A complete, data-anchored patent landscape with specific US competitor patents, expiration dates, assignees, and litigation events cannot be derived from the claim text alone.
FAQs
1) If a competitor sells a Formula III compound but does not market it for type 1 Gaucher, does Claim 1 still carry risk?
Risk depends on actual method practice and evidence of treating type 1 Gaucher. Claim 1 requires treating “type 1 Gaucher’s disease.”
2) Can a product avoid Claim 3 by combining the Formula III compound with a therapy other than imiglucerase or miglustat?
Yes. Claim 3 requires the other therapeutic agent to be imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol.
3) How do you design around the claim if R³ must be fluorine?
Change the substitution pattern so that the group corresponding to R³ is not fluorine in the accused structure, or change the scaffold so it no longer satisfies the Formula III R-group definitions.
4) Which dependent claims are easiest to trigger if infringement is close on the chemical genus?
Claims 4–8 act as subgroup “falls backs” by pinning R² and R⁴ to enumerated values. If the accused compound matches one subgroup, those claims are easier to map than the broader genus under Claim 1.
5) Is the combination limitation “further comprising” likely to be interpreted as optional or required?
It is required in the sense that the method must also administer the additional therapeutic agent specified by the dependent claims.
References
- US Patent 10,035,766 (claims provided in prompt).
